Pharmacyte Biotech Stock Analysis
| PMCB Stock | USD 1.58 0.09 5.39% |
PharmaCyte Biotech is overvalued with Real Value of 1.36 and Hype Value of 1.58. The main objective of PharmaCyte Biotech stock analysis is to determine its intrinsic value, which is an estimate of what PharmaCyte Biotech is worth, separate from its market price. There are two main types of PharmaCyte Biotech's stock analysis: fundamental analysis and technical analysis.
The PharmaCyte Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and PharmaCyte Biotech's ongoing operational relationships across important fundamental and technical indicators.
PharmaCyte |
PharmaCyte Stock Analysis Notes
The company has price-to-book ratio of 0.27. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PharmaCyte Biotech had not issued any dividends in recent years. The entity had 1:1550 split on the 12th of July 2021. PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Pharmacyte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. To find out more about PharmaCyte Biotech contact Joshua Silverman at 917-595-2850 or learn more at https://pharmacyte.com.PharmaCyte Biotech Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. PharmaCyte Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding PharmaCyte Biotech or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| PharmaCyte Biotech may become a speculative penny stock | |
| PharmaCyte Biotech had very high historical volatility over the last 90 days | |
| PharmaCyte Biotech has high likelihood to experience some financial distress in the next 2 years | |
| PharmaCyte Biotech currently holds about 82.23 M in cash with (2.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
PharmaCyte Biotech Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to PharmaCyte Biotech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View |
PharmaCyte Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.85 M.Technical Drivers
As of the 24th of March, PharmaCyte Biotech holds the Coefficient Of Variation of 7060.18, semi deviation of 3.16, and Risk Adjusted Performance of 0.0203. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of PharmaCyte Biotech, as well as the relationship between them.PharmaCyte Biotech Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. PharmaCyte Biotech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for PharmaCyte Biotech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
PharmaCyte Biotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific PharmaCyte Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on PharmaCyte Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases PharmaCyte Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Weinstein Robert over a month ago Acquisition by Weinstein Robert of 38009 shares of PharmaCyte Biotech at 2.12 subject to Rule 16b-3 | ||
Schmieg Martin over three months ago Disposition of tradable shares by Schmieg Martin of PharmaCyte Biotech subject to Rule 16b-3 | ||
Liquard Thomas over three months ago Disposition of 167 shares by Liquard Thomas of PharmaCyte Biotech at 156.0 subject to Rule 16b-3 | ||
Tong Raymond Cf over six months ago Disposition of 334 shares by Tong Raymond Cf of PharmaCyte Biotech at 51.0 subject to Rule 16b-3 | ||
Schmieg Martin over six months ago Disposition of tradable shares by Schmieg Martin of PharmaCyte Biotech subject to Rule 16b-3 | ||
Tong Raymond Cf over six months ago Disposition of 334 shares by Tong Raymond Cf of PharmaCyte Biotech at 51.0 subject to Rule 16b-3 | ||
Michael Abecassis over a year ago Acquisition by Michael Abecassis of 61248 shares of PharmaCyte Biotech subject to Rule 16b-3 |
PharmaCyte Biotech Outstanding Bonds
PharmaCyte Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. PharmaCyte Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most PharmaCyte bonds can be classified according to their maturity, which is the date when PharmaCyte Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| PHARMACIA P 66 Corp BondUS71713UAW27 | View | |
| PHARMACIA P 675 Corp BondUS71713UAT97 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
PharmaCyte Biotech Predictive Daily Indicators
PharmaCyte Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of PharmaCyte Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
PharmaCyte Biotech Forecast Models
PharmaCyte Biotech's time-series forecasting models are one of many PharmaCyte Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PharmaCyte Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About PharmaCyte Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how PharmaCyte Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling PharmaCyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as PharmaCyte Biotech. By using and applying PharmaCyte Stock analysis, traders can create a robust methodology for identifying PharmaCyte entry and exit points for their positions.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Pharmacyte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding PharmaCyte Biotech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Price Exposure Probability Now
Price Exposure ProbabilityAnalyze equity upside and downside potential for a given time horizon across multiple markets |
| All Next | Launch Module |
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |